证券代码：300406 证券简称：九强生物 公告编号：2025-055 转债代码：123150 转债简称：九强转债 北京九强生物技术股份有限公司 关于"九强转债"转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》以下简称（"《募集说明书》"）相关条款的规定，在本次可转债发行 之后，当公司因派送股票股利、转增股本、增发新股（不包括因本次可转债转股而增 加的股本）、配股、派送现金股利等情况使公司股份发生变化时，将按下述公式进行 转股价格的调整（保留小数点后两位，最后一位四舍五入）： 派送股票股利或转增股本：P1=P0/(1+n) 当公司出现上述股份和/或股东权益变化情况时，将依次进行转股价格调整，并 在深圳证券交易所网站和中国证券监督管理委员会指定的上市公司信息披露媒体上刊 登董事会决议公告，并于公告中载明转股价格调整日、调整办法及暂停转股期间（如 需）。当转股价格调整日为本次可转债持有人转股申请日或之后、 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-054 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销涉及人数 51 人，回购注销的股份合计 2,017,966 股， 占注销前北京九强生物技术股份有限公司（以下简称"公司"）总股本（因 公司公开发行的可转换公司债券"九强转债"处于转股期，本公告中"总股 本"均指截至 2025 年 7 月 11 日公司总股本 588,326,594 股。）的 0.34%。 第五期限制性股票激励计划因激励对象离职回购注销限制性股票 16,817 股，回购价格为 9.32 元/股。除此之外，因公司层面业绩考核不达标 回购注销首次授予第二个解除限售期及预留授予第一个解除限售期限制性 股票 2,001,149 股，其中，首次授予 1,832,988 股，回购价格为 9.32 元/ 股；预留授予 168,161 股，回购价格为 9.20 元/股。综上，本次拟回购注销 限制性股票共计 ...

本发明涉及一种肌酸激酶同工酶检测试剂盒。该试剂盒包括第一试剂、第二 试剂。第一试剂包含缓冲液、防腐剂、增凝剂、表面活性剂、保护剂、阻断剂； 第二试剂包含缓冲液、稳定剂、防腐剂、保护剂、聚苯乙烯胶乳颗粒、肌酸激酶 同工酶抗体。本发明的试剂盒具有稳定性好、特异性强等优点，能够应用于生化 仪进行大批量的测定，能够替代化学发光产品，降低医院测定成本。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司" ）于 近期收到美国专利局颁发的 1 项专利证书，具体情况如下： 注：发明专利权期限为自申请日起二十年。 发明专利摘要： | 债券代码：123150 | 债券简称：九强转债 | | | --- | --- | --- | | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-053 | 北京九强生物技术股份有限公司 关于公司获得发明专利证书的公告 二、对公司的影响 上述发明专利证书的取得不会对公司近期生产经营产生重大影响，但有利于 发挥公司的知识产权优势，促进技术创新，提升公司的核心竞争力，并形 ...

Core Viewpoint - The AI Fund Zhaoshang Frontier Healthcare Stock A (011373) reported a profit of 41.645 million yuan for Q2 2025, with a fund net value growth rate of 7.89% and a total fund size of 570 million yuan as of the end of Q2 2025 [2][12]. Fund Performance - The fund's weighted average profit per share for the reporting period was 0.0404 yuan [2]. - As of July 17, the unit net value was 0.625 yuan [2]. - The fund's performance over various time frames includes a 32.00% growth rate over the last three months, 43.06% over the last six months, and 42.96% over the last year, ranking 22/54 and 21/53 among comparable funds respectively [2]. Fund Management - The fund is managed by Li Jiasun, who oversees four funds, all of which have shown positive returns over the past year [2]. - The fund focuses on sectors with a comparative advantage in certain growth, particularly in innovative drugs, R&D outsourcing, medical devices, and AI healthcare [2]. Risk Metrics - The fund's three-year Sharpe ratio stands at -0.1027, ranking 28/46 among comparable funds [7]. - The maximum drawdown over the last three years was 48.11%, with the largest single-quarter drawdown occurring in Q3 2022 at 26.38% [8]. Investment Strategy - The fund maintains a high stock position, averaging 90.79% over the last three years, with a peak of 94.27% at the end of Q3 2024 [11]. - The fund has a high concentration in its top ten holdings, which have consistently exceeded 60% over the past two years [15].

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于2025年第二季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"九强转债"（债券代码：123150）的转股期限为 2023 年 1 月 6 日至 2028 年 6 月 29 日；最新有效的转股价格为 16.95 元/股。 2、2025 年第二季度，"九强转债"未发生转股情况。 3、截至 2025 年第二季度末，公司剩余可转债为 11,210,221 张，剩余票面 总金额为 1,121,022,100 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，北京九强生物技术股 份有限公司（以下简称"公司"）现将 2025 年第二季度可转换公司债券转股及 公司总股本变化情况公告如下： 一、可转换公司债券发行及上市情况 ...

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 | 一、专利基本情况 | | --- | | 序号 | 专利号 | 专利名称 | 专利权人 专利类型 申请日期 | 授权日期 | 证书号 | | --- | --- | --- | --- | --- | --- | | 1 | 7689563 | 检测待检测 样本的前带 | 九强生物 发明 2023.11.21 | 2025.05.29 | N/A | | | | 现象的量化 | | | | | | | 方法和装置 | | | | 注：发明专利权期限为自申请日起二十年。 发明专利摘要： 本发明涉及检测待检测样本的前带现象的量化方法和装置。方法包括：利用 参考样本的实际的抗原浓度和反应曲线的曲率或长度来构建第一定标曲线；根据 待检测样本计算出的反应曲线的曲率或长度来确定 ...

Core Viewpoint - The credit rating agency has maintained a stable credit rating for Beijing Jiukang Biotechnology Co., Ltd., reflecting its strong technical advantages and profitability in the biochemical immunology and pathological diagnosis sectors, while also highlighting potential risks due to increasing competition in the medical consumables industry [3][5][8]. Company Overview - Beijing Jiukang Biotechnology Co., Ltd. focuses on the research, production, and sales of in vitro diagnostic reagents, with a strong presence in biochemical immunology and pathological diagnosis [3][5]. - The company has a credit rating of AA- with a stable outlook, indicating robust financial health and operational stability [3][8]. Financial Performance - The company's total assets reached 56.31 billion, with equity attributable to shareholders at 42.20 billion as of March 2025 [3][4]. - Revenue for 2024 was reported at 16.59 billion, a decrease of 4.75% year-on-year, while net profit was 5.31 billion, reflecting a decline of 32.08% in the first quarter of 2025 [3][7][17]. - The gross profit margin increased by 3.84 percentage points to 78.50% in 2024, driven by higher sales from its subsidiary, Mai Xin Biotechnology [5][17]. Research and Development - The company increased its R&D investment to 1.89 billion in 2024, a growth of 15.73% year-on-year, with R&D expenses accounting for 11.36% of revenue [5][20]. - The number of medical device registration certificates rose to 379 by the end of 2024, with 228 patents held, indicating a strong focus on innovation [5][19]. Market Position and Competition - The company faces increasing competition in the medical consumables sector, which may impact revenue and profit margins if its technological advantages diminish [6][7]. - The in vitro diagnostic market in China is projected to grow, with a market size expected to exceed 1,200 billion by 2024, driven by rising health awareness and aging population [15][16]. Risks and Challenges - The company has significant goodwill from acquisitions, which accounted for 29.70% of total assets as of March 2025, posing a risk of impairment if acquired entities do not perform as expected [7][8]. - There is a reliance on imported raw materials for production, which could lead to supply shortages or price instability [6][23].

Company Overview - Beijing Jiukang Biological Technology Co., Ltd. specializes in the research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - The main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, and laboratory auxiliary services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 320 million yuan, a year-on-year decrease of 18.81% [1] - The net profit for the same period was 83.26 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1] Market Position - The company's current stock price is 13.58 yuan, with a rolling price-to-earnings (PE) ratio of 16.13 times [1] - The average PE ratio in the medical device industry is 49.45 times, with a median of 35.92 times, placing Jiukang Biological at the 39th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 15,231, a decrease of 547 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Recognition - On February 22, 2023, the company was recognized as a "National Enterprise Technology Center" in the 29th batch of newly identified national enterprise technology centers [1]

北京九强生物技术股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【439】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经 ...